



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Immunology

**ESPS Manuscript NO:** 10368

**Title:** Targeting of TLLing-Ling Wen/MAPKs Signaling Pathway: A Better Option for Immunotherapeutic Inhibition of Atherosclerosis

**Reviewer code:** 02638028

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-03-31 10:34

**Date reviewed:** 2014-04-05 12:25

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

This is a well written and illustrated paper about TLR4/MAPKs signaling pathway in the process of atherosclerosis. I have annotated the manuscript with several minor corrections. There are unnecessary repetitive explanations of the abbreviation "TLR" (P3L93, P6L181, P6L190, P7L210,,). In P4L127, TLR4might→TLR4 might. In P5L152, what are plaque cells?



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Immunology

**ESPS Manuscript NO:** 10368

**Title:** Targeting of TLLing-Ling Wen/MAPKs Signaling Pathway: A Better Option for Immunotherapeutic Inhibition of Atherosclerosis

**Reviewer code:** 00572158

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-03-31 10:34

**Date reviewed:** 2014-04-11 15:42

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

This manuscript is a review bringing up an idea that inhibition of TLR4/MAPKs signaling pathway may have therapeutic efficacy of atherosclerosis. According to what the authors emphasize here, TLR4 can induce proatherogenic effect through MAPKs signaling. Therefore, interferences in the TLR4/MAPKS signaling pathway probably inhibit atherosclerosis progression. However, in order to make the readers fully understand the messages of the article, there are several points which should need to be revised. Major points: 1. The sections in the article should be reorganized. The arrangement of each section should follow the logic of the authors' idea step by step. The current organization of this review is kind of confusing. The background information of TLR4 is redundant in several places. In contrary, the section of "Toll-Like Receptor-4 (TLR4)" is too brief. Additionally, some paragraphs are not that fitting their subject. For example, line 123-128 should belong to TLR4-related sections. 2. Base on the title, the authors intend to talk about the immunotherapies of atherosclerosis by targeting on TLR4/MAPKs pathway; however, the description of the idea is too little and not depth enough in the article. Minor points: There are many mistakes in the manuscript, such as formats of references, spelling, capitals, and abbreviations. Some examples are as following: 1. The statement of lines 104-109 is not consistent with Reference 11. 2. The common words and phrases should be spelled out and abbreviated when first used. Abbreviations should be used later. There are some mistakes in the text. 3. The sentence of lines 236-241 is complex and unclear. 4. In References section, Reference 1 is on pages 204-212. (Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011; 12: 204-212.) The authors' names are wrong. 5. In



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)

<http://www.wjgnet.com>

---

References section, Reference 9 is identical to Reference 32. 6. In line 156 and 157, there are spelling mistakes. The word My88 should be MyD88. 7. In line 187, there is a spelling mistake. The word adventitional should be adventitial. 8. In line 104, capitals should not be within the sentence.



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

http://www.wjgnet.com

## ESPS Peer-review Report

**Name of Journal:** World Journal of Immunology

**ESPS Manuscript NO:** 10368

**Title:** Targeting of TLLing-Ling Wen/MAPKs Signaling Pathway: A Better Option for Immunotherapeutic Inhibition of Atherosclerosis

**Reviewer code:** 01482015

**Science editor:** Ling-Ling Wen

**Date sent for review:** 2014-03-31 10:34

**Date reviewed:** 2014-04-24 23:34

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

Drs. Janeesh P.A and Annie Abraham wrote a good review of targeting of the TLR4 and MAPKs pathway for atherosclerosis. The major concern: There were too fewer reviews regarding the current development of medicine/ drug targeting the TLR4 and MAPKs pathway. Here are some references:

1. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. *Cancer Lett.* 2013 Dec 1;341(2):139-49. doi: 10.1016/j.canlet.2013.08.023.
2. Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells. *J Cardiovasc Pharmacol.* 2011 Mar;57(3):348-56.
3. Salvianolic acid B suppresses maturation of human monocyte-derived dendritic cells by activating PPAR $\gamma$ . *Br J Pharmacol.* 2011 Dec;164(8):2042-53. doi: 10.1111/j.1476-5381.2011.01518.x.

Suggestions: The authors should enrich the evidence of the pharmaceutical target on this pathway and discuss.